Quick Answer
KalVista Pharmaceuticals, Inc. reported Net Income of -$183.44 million for fiscal year 2025.
KalVista Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$183.44M | -44.9% |
| 2024 | -$126.64M | -36.3% |
| 2023 | -$92.91M | -12.8% |
| 2022 | -$82.34M | -78.1% |
| 2021 | -$46.24M | -58.8% |
| 2020 | -$29.12M | -39.9% |
| 2019 | -$20.82M | -31.7% |
| 2018 | -$15.80M | +15.0% |
| 2017 | -$18.60M | -62.7% |
| 2016 | -$11.44M | +54.0% |
| 2015 | -$24.85M | -243.8% |
| 2015 | -$7.23M | +45.9% |
| 2014 | -$13.36M | -135.3% |
| 2013 | -$5.68M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$49.48M | -26.6% | +17.7% |
| July 31, 2025 | -$60.10M | -48.6% | -4.3% |
| June 30, 2025 | -$57.60M | -42.8% | -11.1% |
| March 31, 2025 | -$51.84M | -20.3% | -6.9% |
| January 31, 2025 | -$48.51M | -67.1% | -14.8% |
| October 31, 2024 | -$42.27M | -52.9% | -8.1% |
| September 30, 2024 | -$39.08M | — | +3.4% |
| July 31, 2024 | -$40.44M | — | -0.3% |
- KalVista Pharmaceuticals, Inc. showed a decrease of -44.9% in Net Income compared to the prior fiscal year.
- Over the 2013–2025 period, KalVista Pharmaceuticals, Inc.’s net income has declined by 3130.8% (from -$5.68 million to -$183.44 million).
- The most recent figure is from KalVista Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 10, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: